Hypoactive Sexual Desire Disorder

3
Pipeline Programs
1
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

On Market (1)

Approved therapies currently available

U
VYLEESI (AUTOINJECTOR)Approved
bremelanotide
Unknown Company
subcutaneous2019

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Palatin Technologies
2 programs
2
BremelanotidePhase 3Peptide1 trial
BremelanotidePhase 3Peptide1 trial
Active Trials
NCT02338960CompletedEst. Jun 2017
NCT02333071CompletedEst. Jun 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Palatin TechnologiesBremelanotide
Palatin TechnologiesBremelanotide

Clinical Trials (2)

NCT02338960Palatin TechnologiesBremelanotide

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Start: Jan 2015Est. completion: Jun 2017
Phase 3Completed
NCT02333071Palatin TechnologiesBremelanotide

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Start: Dec 2014Est. completion: Jun 2017
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space